

Supporting Information

Association of COVID-19 risk factors with systemic fungal infections in hospitalized patients

Abbygail C. Wilbourn,^{a,*} Oleg V. Tsodikov,^{a,*} and Sylvie Garneau-Tsodikova ^{a,*}

^a University of Kentucky, College of Pharmacy, 789 South Limestone St., Lexington, KY, 40536-0596, USA.

* Correspondence to: spency05@gmail.com or oleg.tsodikov@uky.edu or sylvieghtsodikova@uky.edu




Figure S1. The age distribution of the patients. **A.** The age distribution in the non-infected group (pink bars). **B.** The age distribution in the infected group (orange bars).




Figure S2. The incidence of systemic fungal infections in this study, grouped by the fungal pathogen.

Tables

Table S1. Characteristics of the patients without and with systemic fungal infections.

	4,952 COVID-19 patients without fungal infection	47 COVID-19 patients with fungal infection
Gender, male n (%), p = 0.194	2267 (46%)	26 (55%)
Race, white n (%)*, p = 0.009	3734 (75%)	44 (94%)
Median age in years (IQR)*, p <0.001	41 (35)	67 (18)
Median height in cm (IQR), p = 0.227	170.0 (15.3)	170.1 (13.4)
Median weight in kg (IQR), p = 0.745	85.2 (32.6)	87.6 (33.7)
Admit to ICU, n, (%)*, p <0.001	222 (4%)	20 (43%)
Transferred from another hospital, n (%)*, p <0.001	572 (12%)	30 (64%)
Median length of hospital stay in h (IQR)*, p <0.001	12 (34)	524 (575)

Abbreviations: ICU = intensive care unit, IQR = interquartile range.
* = statistically significant difference between the two groups

Table S2. Clinical characteristics of the patients without and with systemic fungal infections.

	4,952 COVID-19 patients without fungal infection	47 COVID-19 patients with fungal infection
Mechanically ventilated hospitalizations, n (%)*, p <0.001	339 (6.8%)	29 (62%)
Median duration of mechanical ventilation, h (IQR)*, p < 0.001	208 (316)	488 (579)
Diabetes mellitus, n (%)*, p <0.001	616 (12%)	24 (51%)
Cardiovascular disease, n (%)*, p <0.001	684 (14%)	26 (55%)
Obesity, n (%)*, p <0.001	337 (7%)	14 (28%)
Mortality, n (%)*, p < 0.001		
In hospital*, OR = 11.0 (95% C.I.: 5.9-20.7)	202 (4%)	15 (32%)
30-day post-discharge*, OR = 12.1 (95% C.I.: 6.5-22.2)	222 (4.5%)	17 (36%)
90-day post-discharge*, OR = 12.3 (95% C.I.: 6.8-22.6)	237 (4.8%)	18 (38%)

* = statistically significant difference between the two groups; OR = odds ratio; C.I. = confidence interval.

Table S3. COVID-19 therapy administrations.

COVID therapy	4,952 COVID-19 patients without fungal infection		47 COVID-19 patients with fungal infection	
	Administrations (per patient)	Patients (%)	Administrations (per patient)	Patients (%)
Remdesivir	2914 (5)	590 (12%)	110 (6)	18 (32%)
Tocilizumab	27 (1)	27 (0.5%)	0 (0)	0 (0)
Dexamethasone	5472 (7)	831 (17%)	357 (11)	32 (68%)
Prednisone	1131 (8)	138 (3%)	141 (11)	13 (28%)
Methylprednisolone	2059 (14)	153 (3%)	213 (18)	12 (26%)
Fludrocortisone	140 (7)	21 (0.4%)	12 (4)	3 (6%)
Hydrocortisone	1119 (10)	109 (2%)	227 (18)	13 (28%)
Prednisolone	12 (6)	2 (0.04%)	0 (0)	0 (0)

Table S4. Steroid administration in dexamethasone equivalents.

	4,952 COVID-19 patients without fungal infection	47 COVID-19 patients with fungal infection
Total mg median (IQR)*, p <0.001	42 (48)	95.25 (257)
Max total mg	2209	1081.5
Min total mg	1.5	7.5
Total administrations median (IQR)*, p <0.001	7 (7)	13 (28.25)
Max total administrations	225	92
Min total administrations	1	1

* = statistically significant difference.

	4,952 COVID-19 patients without fungal infection		47 COVID-19 patients with fungal infection	
Vaccine manufacturer	<i>All vaccinations</i>	<i>Patients (%)</i>	<i>All vaccinations</i>	<i>Patients (%)</i>
Pfizer-BioNTech	409	308 (6.2%)	0	0
Moderna	152	111 (2.2%)	0	0
Janssen	5	5 (0.1%)	0	0

Predictor	OR all infections	OR candidiasis	OR aspergillosis
Age, $\geq 50 / < 50$	7.9 (3.7-16.9) ^a , p < 0.001	16 (5-51), p < 0.001	14 (2-114), p = 0.011
Race, white/other	4.8 (1.5-15.4), p = 0.009	4.9 (1.2-20.4), p = 0.03	p = 0.3
ICU admission	16 (9-29), p < 0.001	12 (6-26), p < 0.001	81 (17-385), p < 0.001
Mechanical ventilation status	22 (12-40), p < 0.001	17 (8-34), p < 0.001	51 (11-243), p < 0.001
Length of hospital stay, ≥ 13 days / < 13 days	42 (21-83), p < 0.001	32 (15-70), p < 0.001	$+\infty$; * all infected patients ≥ 13 d
Diabetes mellitus	7.3 (4.1-13.1), p < 0.001	7.0 (3.5-14.0), p < 0.001	10 (3-37), p < 0.001
Cardiovascular disease	7.7 (4.3-13.8), p < 0.001	9.0 (4.4-18.4), p < 0.001	4.0 (1.1-14.4), p < 0.031
Obesity	5.8 (3.1-11.0), p < 0.001	6.2 (2.9-13.1), p < 0.001	8.9 (2.5-31.8), p = 0.001
Remdesivir	5.0 (2.8-9.0), p < 0.001	4.4 (2.1-9.0), p < 0.001	11 (3-39), p < 0.001
Steroids (any administration of any steroid)	23 (10-52), p < 0.001	14 (6-33), p < 0.001	$+\infty$; * all infected patients + steroids
Lack of COVID-19 vaccination	$+\infty$; * all infected patients	$+\infty$; * all infected patients	$+\infty$; * all infected patients – vaccine

^aThe OR ranges correspond to 95% confidence intervals.
*The statistical significance and the OR range could not be calculated due to the lack of patients or only one patient in one of the categories.